Back to discover
Drug

Maraviroc

Approved · EMA
Emerging researchLate-stage developmentRising momentum

Also known as Selzentry, Maravirocum.

RxNorm620216ChEMBLCHEMBL1201187UNIIMD6P741W8A
3
Research papers
8
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)

Clinical trial2026-07-30Primary completion · ClinicalTrials.gov

A Novel Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies

Clinical trial2026-06-30Results expected Q3 2029 · ClinicalTrials.gov

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

Clinical trial2026-06-18Results expected Q4 2026 · ClinicalTrials.gov

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Use of Antiretrovirals

Clinical trial2026-06-01Results expected Q1 2027 · ClinicalTrials.gov

Investigating the Feasibility of Repurposing HIV Antivirals in Adults With Long Covid

Clinical trial2026-03-13Results expected Q4 2026 · ClinicalTrials.gov

A Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction Immunosuppression

Clinical trial2026-01-20Results expected Q2 2028 · ClinicalTrials.gov

The CAMAROS Trial: The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke

Clinical trial2025-12-01Primary completion · ClinicalTrials.gov

Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial

Clinical trial2025-08-12Results expected Q4 2027 · ClinicalTrials.gov

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects.

Research2019-10-24PloS one

Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.

Research2016-02-01AIDS (London, England)

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.

Research2011-10-10The Journal of antimicrobial chemotherapy

Approval: Celsentri (EMA)

Regulatory2007-09-18EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Maraviroc
Aliases & brands
SelzentryMaravirocum
RxNorm CUI
620216
ChEMBL ID
CHEMBL1201187
UNII
MD6P741W8A
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2007-09-18
Latest approval
2007-09-18
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2007-09-18Approval
Approval: Celsentri (EMA)
Indication: Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and… Show full indication

Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

101 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
101
registered trials across all phases
LATEST COMPLETION 2022
8
Active studies
8
Recruiting
46
Late-stage (III+)
74
Completed
19
Discontinued
PHASE DISTRIBUTIONn = 101
Early Phase 11Phase 125Phase 1 / 24Phase 225Phase 2 / 38Phase 38Phase 425Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Novel Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies

Not yet recruitingPH IVChinese University of Hong Kongn=102029

The Role of Home Packs of HIV Post-Exposure Prophylaxis for Sexual Exposure (PEPSE) to Improve the Speed and Appropriate Uptake of PEPSE in High Risk Individuals

CompletedPH IVGuy's and St Thomas' NHS Foundation Trustn=1392021

A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV

CompletedPH IVNational Institute of Allergy and Infectious Diseases (NIAID)n=1912021

A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C

CompletedPH IVUniversity of Maryland, Baltimoren=102019

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

CompletedPH IVUniversity Of Perugian=222017

Recent completions

Trials that read out recently, adding to the completed evidence base.

Safety of Maraviroc for Post-stroke Depression (Proof-of-concept)

CompletedPH IITel-Aviv Sourasky Medical Centern=102022

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

CompletedPH IINational Institute of Allergy and Infectious Diseases (NIAID)n=972022

The Role of Home Packs of HIV Post-Exposure Prophylaxis for Sexual Exposure (PEPSE) to Improve the Speed and Appropriate Uptake of PEPSE in High Risk Individuals

CompletedPH IVGuy's and St Thomas' NHS Foundation Trustn=1392021

A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV

CompletedPH IVNational Institute of Allergy and Infectious Diseases (NIAID)n=1912021

Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2

CompletedPH IRhode Island Hospitaln=92020

A Multicentre, 48 Week Randomised Controlled Factorial Trial of Adding Maraviroc and/or Metformin for Hepatic Steatosis in HIV-1-infected Adults on Combination Antiretroviral Therapy.

CompletedPH II/IIIUniversity College, Londonn=902020

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20122019
Major research themes3
CCR5 Receptor Antagonists1Cognition1Drug Interactions1
Journals, researchers & institutions
Top journals
  • AIDS (London, England)1
  • PloS one1
  • The Journal of antimicrobial chemotherapy1
Leading researchers
  • Allsop JM1
  • Back D1
  • Brew BJ1
  • Cameron DW1
  • Chaganti J1
  • Cysique LA1
  • Dennehy M1
  • Erlwein OW1
Leading institutions
free-text, unnormalised
  • Clinical Epidemiology Program1
  • Clinical Investigation Unit1
  • Imperial College London1
  • Ottawa Hospital Research Institute1
  • Ottawa Methods Centre1
  • St Vincent's Hospital and Peter Duncan Neurosciences Unit1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.